Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
High frequency of BRAF mutations in nevi
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
